Pancreatic Cancer Research

ResearcherUniversity of Nebraska–LincolnActive in the last 2 years

Razelle Kurzrock

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-4110-1214; OpenAlex author ID A5003304495, A5053481267. Sources: ClinicalTrials.gov.

Their work

Papers
15 (first author 2, last author 5)
Trials
3 (principal investigator on 2)
Grants
0
Labs led
1
Collaborators
58
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: 2 papers, 1 trial · 2022: 1 trial · 2023: 2 papers · 2024: 3 papers, 1 trial · 2025: none · 2026: 4 papers

Papers 15

  1. Advancing precision medicine in pancreatic cancer using novel biomarkers and clinical targets. Co-author DOI 10.1016/j.mam.2026.101476↗
  2. MEK inhibitor-based genomically matched combinatorial targeted therapies in metastatic pancreatic adenocarcinoma with KRAS alterations. Co-author DOI 10.1093/oncolo/oyag040↗
  3. Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenoca… Co-author DOI 10.1158/0008-5472.can-25-0018↗
  4. Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-26-1181↗
  5. Pan-cancer analysis of TIM-3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneity. First author DOI 10.1002/cam4.6844↗
  6. Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2024.01.028↗
  7. Chemotherapy-free treatment targeting fusions and driver mutations in KRAS wild-type pancreatic ductal adenocarcinoma, a case series. Co-author DOI 10.1177/17588359241253113↗
  8. Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis. Last author DOI 10.1038/s41525-022-00346-5↗
  9. Development of a blood-based extracellular vesicle classifier for detection of early-stage pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s43856-023-00351-4↗
  10. SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer. Last author DOI 10.1172/jci.insight.150453↗
  11. Immune profiling and immunotherapeutic targets in pancreatic cancer. Co-author DOI 10.21037/atm-20-1076↗
  12. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer. Last author DOI 10.1186/s13045-019-0824-4↗
  13. The effects of curcumin (diferuloylmethane) on body composition of patients with advanced pancreatic cancer. Last author DOI 10.18632/oncotarget.7773↗
  14. Molecular landscape of pancreatic cancer: implications for current clinical trials. First author DOI 10.18632/oncotarget.2972↗
  15. Phase 1 clinical trials in 83 patients with pancreatic cancer: The M. D. Anderson Cancer Center experience. Last author DOI 10.1002/cncr.25346↗

Trials 3

  1. Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence Principal investigator NCT06228599↗
  2. Investigation of Profile-related Evidence Determining Individualized Cancer Therapy for Patients With Aggressive Malignancies and Poor Prognoses Principal investigator NCT05674825↗
  3. The Registry of Oncology Outcomes Associated With Testing and Treatment Study chair NCT04028479↗

Closest collaborators

The 25 strongest of 58 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mandana Kamgar · 5 shared papers, 1 shared trial, 2024–2026 · strength 1.55
  2. Thomas B. McFall · 5 shared papers, 2024–2026 · strength 1.01
  3. Shumei Kato · 5 shared papers, 2019–2024 · strength 0.76
  4. Douglas B. Evans · 4 shared papers, 2024–2026 · strength 0.74
  5. Susan Tsai · 4 shared papers, 2024–2026 · strength 0.74
  6. Mohammed Aldakkak · 3 shared papers, 2026 · strength 0.68
  7. Douglas B. Evans · 1 shared trial, 2024 · strength 0.54
  8. William Adrian Hall · 3 shared papers, 2024–2026 · strength 0.54
  9. Kathleen K. Christians · 3 shared papers, 2024–2026 · strength 0.54
  10. Hui-Zi Chen · 1 shared trial, 2022 · strength 0.49
  11. Sam Z. Thalji · 2 shared papers, 2026 · strength 0.48
  12. Nikki K. Lytle · 2 shared papers, 2026 · strength 0.41
  13. Yongwoo David Seo · 2 shared papers, 2026 · strength 0.41
  14. Daniel Dorbin · 2 shared papers, 2026 · strength 0.41
  15. G. Aaron Hobbs · 2 shared papers, 2026 · strength 0.41
  16. Ben George · 2 shared papers, 2024–2026 · strength 0.38
  17. Beth E. Erickson · 2 shared papers, 2024–2026 · strength 0.38
  18. Gregory P. Botta · 2 shared papers, 2021–2023 · strength 0.34
  19. Hitendra Patel · 2 shared papers, 2019–2023 · strength 0.29
  20. Jennifer Johnson · 1 shared trial, 2021 · strength 0.29
  21. Vivek Subbiah · 1 shared trial, 2021 · strength 0.29
  22. Raymond Bergan · 1 shared trial, 2021 · strength 0.29
  23. Elizabeth Diane Auckley · 1 shared paper, 2026 · strength 0.27
  24. Andrew Karam · 1 shared paper, 2026 · strength 0.26
  25. Divya Murthy · 1 shared paper, 2026 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.